Northstar Biopharma Solutions

Precision without compromise.
Powering research from blood.

DNA Image Decorative BackgroundDNA Image Decorative Background

Unlock more from every drop of blood.

At BillionToOne, we build ultra-sensitive, liquid-only oncology assays that expand and accelerate what’s possible in biomarker driven drug development.

Our proprietary Quantitative Counting Templates™ (QCT) technology unlocks single-molecule precision from ctDNA—allowing you to detect variants and signals that other tests miss.

Get in Touch
A graph titled "Precision of measurement" shows the relationship between the coefficient of variation (%CV) and the number of loci assayable (plex-ability). The y-axis represents %CV on a logarithmic scale from 100% to 1%, while the x-axis represents the number of loci assayable from 1 to 1000+. A downward sloping white curve shows increasing plex-ability results in lower precision. ddPCR is marked near 1% CV and low plex-ability, and NGS is marked at higher plex-ability but lower precision. A blue label highlights "BillionToOne's QCT-enabled NGS encoding," indicating high plex-ability with improved precision near 1% CV.

Our Biopharma Platform Supports:

Plus Icon

Clinical Development

Accelerate pivotal trials with sensitive, non-invasive tools for patient selection and real-time monitoring — enabling faster enrollment and reducing time to trial completion.

Search Icon

Translational Research

Explore tumor biology and optimize variant identification of low frequency mutations or in low-shedding tumors.

Arrow Up Icon

CDx Programs

With ultra-sensitive liquid biopsy and a scalable platform, Northstar supports confident development from early-phase expansion.

Our Oncology Assays

Linearity of Tumor Methylation Score as measured in contrived samples made from a breast, colorectal, and lung tumor. Chart.

Assay Highlights3

  • >2200 cancer related loci, methylation based ctDNA signature

  • LOD = 0.01% tumor fraction

  • Single-molecule level resolution powered by QCT™

  • Sub-clonal methylation pattern change provides additional insights into tumor evolution

Discover Northstar Response
VAF Distribution of Clinically Actionable and/or Pathogenic SNVs/Indels Chart

Assay Highlights

  • Detects up to 50% more variants from blood than other liquid CGP assays in a landmark head-to-head study

  • Unmatched CNA calls for amplifications or losses

  • Determines focal vs. aneuploidy amplification

  • Reduces false-negative reports by half

Discover Northstar Select

Work with us to accelerate your R&D portfolio

Get in Touch

  • Based on a head-to-head clinical study [Bower, X., et al., JCO 42, 3072-3072(2024)].

  • *LOD 95% (Limit of Detection 95%) is defined as the lowest concentration of an analyte in a sample that can be consistently detected with ≥95% probability. Comparator assays have a LOD 95% that ranges from 0.20% -0.40%.

  • Analytical validation data on file